These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 4060076)

  • 21. Combo drug therapy beneficial for new cases of multiple myeloma.
    Health News; 2006 Feb; 12(2):9. PubMed ID: 16456922
    [No Abstract]   [Full Text] [Related]  

  • 22. [Prognostic value of some biochemical and immunologic factors in the management of multiple myeloma].
    Abdulkadyrov KM; Stel'mashenko LV; Bessmel'tsev SS; Lubo-Lesnichenko IF; Sel'tser AV; Rozanova OE; Gubarenko NK; Bubnova LN; Mnuskina MM; Zhuchikhina AA; Blinov MN; Gritskevich NL
    Vopr Onkol; 1998; 44(3):304-9. PubMed ID: 9695777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thalidomide with continuous low-dose dexamethasone for multiple myeloma.
    Gardyn J
    J Clin Oncol; 2005 Feb; 23(6):1323. PubMed ID: 15718336
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment of multiple myeloma. A small step forward?
    Kyle RA
    N Engl J Med; 1984 May; 310(21):1382-4. PubMed ID: 6371531
    [No Abstract]   [Full Text] [Related]  

  • 25. Thalidomide and dexamethasone in patients with multiple myeloma not undergoing upfront autologous stem cell transplantation.
    Blade J
    Haematologica; 2005 Dec; 90(12):1589. PubMed ID: 16330426
    [No Abstract]   [Full Text] [Related]  

  • 26. Advances in the treatment of elderly patients with multiple myeloma.
    Facon T
    Clin Adv Hematol Oncol; 2006 Jul; 4(7):501-2. PubMed ID: 17147234
    [No Abstract]   [Full Text] [Related]  

  • 27. High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
    Gertz MA; Lacy MQ; Dispenzieri A; Hayman SR; Kumar SK
    Expert Rev Anticancer Ther; 2006 Mar; 6(3):343-60. PubMed ID: 16503852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Combination chemotherapy (modified M-2 protocol) for multiple myeloma].
    Iwata Y; Karitani Y; Tanaka I; Kobayashi T; Ohno T; Kageyama S; Katayama N; Kataoka Y; Kamio N; Ohota C
    Rinsho Ketsueki; 1984 Sep; 25(9):1380-7. PubMed ID: 6549187
    [No Abstract]   [Full Text] [Related]  

  • 29. [Chemotherapy of plasmacytoma].
    Kraj M
    Pol Tyg Lek; 1983 Apr; 38(16):477-80. PubMed ID: 6356085
    [No Abstract]   [Full Text] [Related]  

  • 30. Lenalidomide and its role in the management of multiple myeloma.
    Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bortezomib plus melphalan and prednisone for multiple myeloma.
    Tsubokura M; Kami M; Komatsu T
    N Engl J Med; 2008 Dec; 359(24):2613; author reply 2613-4. PubMed ID: 19090031
    [No Abstract]   [Full Text] [Related]  

  • 32. Successful treatment with VAD of a myelodysplastic syndrome occurring during the course of a smoldering multiple myeloma.
    Cortesão E; Espadana A; Laranjeiro P; Jara M; Orfão A
    Leuk Res; 2009 Jan; 33(1):195-7. PubMed ID: 18511113
    [No Abstract]   [Full Text] [Related]  

  • 33. Bisphosphonates may potentiate effects of thalidomide-dexamethasone combination in advanced multiple myeloma.
    Ural AU; Avcu F
    Am J Hematol; 2006 May; 81(5):385-6; author reply 386. PubMed ID: 16628715
    [No Abstract]   [Full Text] [Related]  

  • 34. [Treatment of multiple myeloma in stages I and II. Comparative study of an M-2 protocol and melphalan-prednisone].
    Montalbán C; Zapatero A; Blanco L; Sevilla F; García Laraña J; Odriozola J
    Sangre (Barc); 1984; 29(6):993-9. PubMed ID: 6549486
    [No Abstract]   [Full Text] [Related]  

  • 35. Myeloma and related disorders.
    Kyle RA; Durie BG; Boccadoro M; Pavlovsky S
    Rev Invest Clin; 1994 Apr; Suppl():46-51. PubMed ID: 7886308
    [No Abstract]   [Full Text] [Related]  

  • 36. Advances in the treatment of multiple myeloma.
    Barlogie B; Jagannath S; Tricot G; Desikan KR; Fassas A; Siegel D
    Adv Intern Med; 1998; 43():279-320. PubMed ID: 9506186
    [No Abstract]   [Full Text] [Related]  

  • 37. Bortezomib plus melphalan and prednisone for multiple myeloma.
    Avvisati G
    N Engl J Med; 2008 Dec; 359(24):2613; author reply 2613-4. PubMed ID: 19090032
    [No Abstract]   [Full Text] [Related]  

  • 38. Role of allogeneic stem cell transplantation in multiple myeloma.
    Thomson KJ; Peggs KS
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):455-64. PubMed ID: 16001953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclophosphamide, doxorubicin, prednisone and vindesine combination chemotherapy in melphalan-resistant multiple myeloma.
    Van Dobbenburgh OA; Houwen B; Piersma H; Marrink J; Ockhuizen T; Halie MR; Nieweg HO
    Neth J Med; 1984; 27(2):25-30. PubMed ID: 6709108
    [No Abstract]   [Full Text] [Related]  

  • 40. Fifth biannual report of the Cochrane Haematologic Malignancies Group--Focus on multiple myeloma.
    Naumann F; Weingart O; Kruse E; Schulz H; Bohlius J; Hülsewede H; Engert A;
    J Natl Cancer Inst; 2006 Aug; 98(16):E2. PubMed ID: 16912255
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.